1987 Volume 1987 Issue Supplement18 Pages 15-27
This report describes the effect of MY-5116, a new preventive drug for type I allergic disease, on the degranulation of basophils and mast cells (metachromatic cells) in nasal fluids of patients with allergic rhinitis induced by house dust antigen in the author's new method of testing allergies. (Once absorbed through the gastro-intestinal tract, MY-5116 is immediately hydrolyzed MY-1250, which has a potent antiallergic effect in animals by inhibiting the release of chemical mediators from mast cells. In this experiment MY-1250 was used instead of MY-5116. )
1) Degranulation occurs when metachromatic cells are stimulated by a-IgE, but not by a-IgA, a-IgD, a-IgM, a-κ, or a-λ. These results suggest that degranulation occurs only when IgE antibodies in receptors on metachromatic cells are bridged with anti-IgE.
2) The specific antigen extracted from allergen by Yagura's method and compound 48/80 also induce degranulation of metachromatic cells in nasal smears. The optimal concentration of the specific antigen is 25μg/ml, and that of compound 48/80 is 0.05μg/ml.
3) When metachromatic cells from healthy subjects are stimulated with anti-IgE,6.8±5.2% of the cells show degranulation. However, when such cells from patients with allergic rhinitis are stimulated with anti-IgE,83.9±11.4% of cells show degranulation.
4) MY-1250 inhibits the specific antigen and compound 48/80 induced degranulation of metachromatic cells of patients with allergic rhinitis. MY-1250 inhibits the degranulation of metachromatic cells when it is added to the metachromatic cells before antigen-stimulation. These data suggest that MY-5116 is a new use- ful preventive and therapeutic drug for allergic rhinitis.
